HAMPS.BO · BSE
HAMPS BIO LIMITED
₹22.95
-10.00% (-₹2.55)
Prev. close
₹25.5
Volume
12,000
As of
17 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About HAMPS BIO LIMITED
Hamps Bio Limited engages in marketing and manufacturing of pharmaceutical, freeze-dried food, and nutraceutical ingredients in India and internationally. It operates through Pharma Products and Freeze-Dried Products segments. The company offers nutrition supplements, injection, pediatric care, toothpaste, mouth wash, antiacid/PPI, painkiller/anti-inflammatory, hematantic/calcium supplement, and antibiotic/antibacterial/antifungal pharmaceutical products. It also offers dry freeze food products, including ingredients for fruit tea / traditional tea, fruit snacks / juice powder, foods, and super food. The company sells its products under the HAMPS and FzyEzy brands through distribution network and e-commerce platform. Hamps Bio Limited was incorporated in 2007 and is based in Surat, India.
Details
Sector
Healthcare
Industry
Pharmaceutical Retailers
CEO
Mr. Herrik Mountbaton Shah
Headquarters
Surat
Employees
51
Website
hampsbio.comExchange
View on BSE ↗Key stats
Market cap
₹19.99 Cr
EPS (TTM)
₹-0.85
Beta (1Y · daily vs NIFTY 50)
0.60
Shares float
21.04 L
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹4.94 Cr | ₹5.94 Cr | ₹6.27 Cr | ₹7.26 Cr | |
| EBITDA | — | ₹86.65 L | ₹1.20 Cr | ₹89.18 L | ₹36.60 L |
| — | ₹35.90 L | ₹50.06 L | ₹29.77 L | ₹-73.90 L | |
| Diluted EPS | ₹0.14 | ₹0.41 | ₹0.57 | ₹0.34 | ₹-0.85 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹3.96 Cr | ₹5.12 Cr | ₹12.79 Cr | ₹15.92 Cr | |
| ₹1.74 Cr | ₹1.05 Cr | ₹2.97 Cr | ₹6.88 Cr | |
| Stockholders' equity | ₹1.36 Cr | ₹3.34 Cr | ₹8.80 Cr | ₹8.10 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹1.23 Cr | ₹-29.15 L | ₹-1.77 Cr | ₹-77.81 L | |
| Investing cash flow | ₹-74.92 L | ₹-36.67 L | ₹-6.21 Cr | ₹-2.86 Cr |
| ₹-48.27 L | ₹66.78 L | ₹8.00 Cr | ₹3.72 Cr | |
| Capital expenditure | ₹-82.91 L | ₹-36.20 L | ₹-3.72 Cr | ₹-5.13 Cr |
| End cash position | ₹4.88 L | ₹5.84 L | ₹9.57 L | ₹16.95 L |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| HAMPS BIO LIMITED | ₹19.99 Cr | ₹22.95 | — | 2.47 | -9.1% | 0.85 | +15.7% | -20.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.